Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology

被引：30

作者：

El Beaino, Marc ^{[1
]}

Roszik, Jason ^{[2
,3
]}

Livingston, John A.

Wang, Wei-Lien ^{[4
]}

Lazar, Alexander J. ^{[4
]}

Amini, Behrang ^{[5
]}

Subbiah, Vivek ^{[6
]}

Lewis, Valerae ^{[1
]}

Conley, Anthony P. ^{[3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Orthopaed Oncol, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Invest Therapeut, Houston, TX 77030 USA

来源：

CURRENT ONCOLOGY REPORTS | 2018年 / 20卷 / 05期

关键词：

Mesenchymal chondrosarcoma; Chondrosarcoma; Fusion; Translocation; Notch; HEY1; NCOA2; IRF2BP2; CDX1; Chromatin remodeling; TGF beta; Apoptosis; Genomics; Pathways; HEY1-NCOA2; FUSION; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; UBIQUITIN LIGASE; PROGENITOR CELLS; GENE FUSIONS; RECURRENT; NOTCH; DIFFERENTIATION; EXPRESSION;

D O I：

10.1007/s11912-018-0668-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mesenchymal chondrosarcoma is a rare but deadly form of chondrosarcoma that typically affects adolescents and young adults. While curative intent is possible for patients with localized disease, few options exist for patients in the unresectable/metastatic setting. Thus, it is imperative to understand the fusion-driven biology of this rare malignant neoplasm so as to lead to the future development of better therapeutics for this disease. This manuscript will briefly review the clinical and pathologic features of mesenchymal chondrosarcoma followed by an appraisal of existing data linked to the fusions, HEY1-NCOA2 and IRF2BP2CDX1, and the associated downstream pathways.

引用

页数：11

共 50 条

[1] Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology
Marc El Beaino
Jason Roszik
John A. Livingston
Wei-Lien Wang
Alexander J. Lazar
Behrang Amini
Vivek Subbiah
Valerae Lewis
Anthony P. Conley
Current Oncology Reports, 2018, 20
[2] Mesenchymal chondrosarcoma of the head and neck with HEY1::NCOA2 fusion: A clinicopathologic and molecular study of 13 cases with emphasis on diagnostic pitfalls
Xu, Bin
Rooper, Lisa M.
Dermawan, Josephine K.
Zhang, Yanming
Suurmeijer, Albert J. H.
Dickson, Brendan C.
Demicco, Elizabeth G.
Antonescu, Cristina R.
GENES CHROMOSOMES & CANCER, 2022, 61 (11) : 670 - 677
[3] Fusion-driven transmutation of fission product cesium in its elemental form
Saito, M
Apse, V
Artisyuk, V
Shmelev, A
JOURNAL OF NUCLEAR SCIENCE AND TECHNOLOGY, 2000, 37 (12) : 1024 - 1031
[4] Genomic profiling identifies genes and pathways dysregulated by HEY1-NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis
Qi, Wenqing
Rosikiewicz, Wojciech
Yin, Zhaohong
Xu, Beisi
Jiang, Huihong
Wan, Shibiao
Fan, Yiping
Wu, Gang
Wang, Lu
JOURNAL OF PATHOLOGY, 2022, 257 (05) : 579 - 592
[5] Agminated presentation of fusion-driven melanocytic neoplasms
Fumero-Velazquez, Monica
Hagstrom, Michael
Dhillon, Soneet
Olivares, Shantel
Jennings, Lawrence. J. J.
Dittman, David
Sukhanova, Madina
Arva, Nicoleta. C. C.
Goldstein, Seth. D. D.
Theos, Amy
Pavlidakey, Peter
Carr, Zachary
Gerami, Pedram
JOURNAL OF CUTANEOUS PATHOLOGY, 2023, 50 (10) : 913 - 921
[6] Conceptual design of the fusion-driven subcritical system FDS-1
Wu, Y
Zheng, S
Zhu, X
Wang, W
Wang, H
Liu, S
Bai, Y
Chen, H
Hu, L
Chen, M
Huang, Q
Huang, D
Zhang, S
Li, J
Chu, D
Jiang, J
Song, Y
FUSION ENGINEERING AND DESIGN, 2006, 81 (8-14) : 1305 - 1311
[7] NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
Laskin, J.
Liu, S., V
Tolba, K.
Heining, C.
Schlenk, R. F.
Cheema, P.
Cadranel, J.
Jones, M. R.
Drilon, A.
Cseh, A.
Gyorffy, S.
Solca, F.
Duruisseaux, M.
ANNALS OF ONCOLOGY, 2020, 31 (12) : 1693 - 1703
[8] p160 nuclear receptor coactivator family members and their role in rare fusion-driven neoplasms (Review)
Segovia, Danilo
Tepes, Polona Safaric
ONCOLOGY LETTERS, 2024, 27 (05)
[9] Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer? -a literature review
Leone, Gianmarco
Passiglia, Francesco
Bironzo, Paolo
Bertaglia, Valentina
Novello, Silvia
TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2674 - 2685
[10] Epigenetic determinants of fusion-driven sarcomas: paradigms and challenges
Stanton, Benjamin Z.
Pomella, Silvia
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12

← 1 2 3 4 5 →